The drug is a combination preparation. The combination of the components of the drug leads to a mutual enhancement of their pharmacological action.
Sodium metamizole is a derivative of pyrazolone, has analgesic, antipyretic and antispasmodic effect. According to research results, metamizole and its active metabolite (4 N-methylaminoantipyrine) have central and peripheral mechanism of action. It nonselectively inhibits cyclooxygenase and reduces formation of prostaglandins from arachidonic acid.
Phenobarbital belongs to the group of barbiturates. It interacts with the barbiturate site of the benzodiazepine-gamma-aminobutyric acid (GABA)-receptor complex, due to which it increases the sensitivity of GABA receptors to GABA, leads to opening of chlorine channels, which increases their flow into the cell and leads to hyperpolarization. Suppresses sensory zones of the cerebral cortex, reduces motor activity, suppresses cerebral functions, including the respiratory center. Decreases the tone of the smooth muscles of the gastrointestinal tract. In small doses has a sedative effect and increases the effect of other components.
Bendazole (dibazole): vasodilator; has a vasodilator effect, stimulates spinal cord function. It has a direct antispasmodic effect on the smooth muscles of blood vessels and internal organs. Facilitates synaptic transmission in the spinal cord.
Papaverine hydrochloride is an antispasmodic agent, it has hypotensive effect, reduces tone and relaxes smooth muscles of internal organs and blood vessels.
Pain syndrome (mild to moderate) associated with spasm of peripheral arteries, smooth muscles of the gastrointestinal tract and urogenital system, blood vessels of the brain, with increased blood pressure.
Hypersensitivity (including to pyrazolone derivatives); inhibition of medullary hematopoiesis; expressed hepatic and/or renal insufficiency; glucose-6-phosphate dehydrogenase deficiency; Children under 8 years of age, pregnancy, lactation, tachyarrhythmias, stable angina pectoris of the III-IV functional class, unstable angina pectoris, spontaneous angina pectoris, collapse, decompensated chronic heart failure; closed-angle glaucoma; prostatic hyperplasia; intestinal obstruction, megacolon, respiratory diseases accompanied by obstructive syndrome; bronchial asthma provoked by taking acetylsalicylic acid, salicylates and other non-steroidal anti-inflammatory drugs; atrioventricular conduction disorder; coma; respiratory depression; advanced age; diseases accompanied by increased muscle tone, seizure syndrome, porphyria (including in anamnesis), myasthenia gravis, alcohol or drug addiction.
Arterial hypotension, peripheral blood diseases, hepatic insufficiency.
Administration during pregnancy and lactation.
The drug is contraindicated in pregnancy and during breast feeding.
There are limited data on the use of sodium metamizole during pregnancy. Sodium metamizole penetrates the placenta. According to the results of preclinical studies, no teratogenic effect of sodium metamizole was found. In spite of the fact that sodium metamizole weakly inhibits prostaglandin synthesis, premature (intrauterine) closure of the arterial duct as well as perinatal complications due to impaired platelet aggregation in the mother or the newborn cannot be excluded.
Sodium metabolites of metamizole penetrate into breast milk; therefore, during the use of the drug and within 48 hours after taking/injection of the last dose it is necessary to give up breastfeeding
Dosage and administration method
- Orally, adults and children over 8 years: 1 tablet 2-3 times a day, not more than 5 days.
- Do not use without consulting a doctor for more than 3 days.